Tag: Health Care
Displaying 121 - 140 of 1394 results.
Pages
The Federal Trade Commission and the U.S. Department of Justice Antitrust Division today issued joint statement detailing an expedited antitrust procedure and providing guidance for collaborations of businesses working to protect the health and safety of Americans during the COVID-19 pandemic.
Danaher Corporation has agreed to divest assets to settle Federal Trade Commission charges that its proposed $21.4 billion acquisition of General Electric’s biopharmaceutical business, GE Biopharma, would violate federal antitrust law.
Proposed development of a relative value guide for physician services to be distributed to member internists would be likely to have anticompetitive effects that probably would not be outweighed by any counterveiling efficiency justifications, Decisions Volume 105
Re: The application of the Non-Profit Institutions Act to sales of pharmaceuticals by non-profit hospitals to related non-profit long-term care facilities, Decisions Volume 116
Re: A program proposed by the American Medical Association and the Chicago Medical Society involving peer review of physician fees is not likely to violate antitrust laws, Decisions Volume 117
The Federal Trade Commission staff has submitted a statement in support of certain changes made by the Department of Health & Human Services’ Office of the National Coordinator for Health Information Technology (ONC) in ONC’s 21st Century Cures Act: Interoperability, Information Blocking Final...
The Federal Trade Commission and U.S. Food and Drug Administration (FDA) have sent warning letters to seven companies allegedly selling unapproved products that may violate federal law by making deceptive or scientifically unsupported claims about their ability to treat coronavirus (COVID-19). The...
The Federal Trade Commission in collaboration with the Food and Drug Administration held a public workshop, "FDA/FTC Workshop on a Competitive Marketplace for Biosimilars." The purpose of the public workshop was to discuss FDA and FTC’s collaborative efforts to support appropriate...
Under a settlement with the Federal Trade Commission, the marketers of an electrical nerve stimulation device called Quell have agreed to pay at least $4 million and stop making deceptive claims that the device treats pain throughout the body when placed below the knee and is clinically proven and...
On March 9, 2020, the Federal Trade Commission and the Food and Drug Administration will co-sponsor a public workshop on promoting competition in biologics markets. The workshop will be held at the FDA’s White Oak Campus in Silver Spring, Maryland and will also be webcast.
The FTC has authorized an action to block the proposed merger of Jefferson Health and Albert Einstein Healthcare Network, two leading providers of inpatient general acute care hospital services and inpatient acute rehabilitation services in both Philadelphia County and Montgomery County,...
The Federal Trade Commission has issued an administrative complaint and authorized an action to block the proposed merger of Jefferson Health and Albert Einstein Healthcare Network, two leading providers of inpatient general acute care hospital services and inpatient acute...
In April 2020, the marketers of three supplements called Neurocet, Regenify, and Resetigen-D settled FTC charges that they deceptively promoted their products to older Americans using false claims that their products could stop pain and treat age-related ailments. The proposed order...
Veterinary service providers Compassion First and National Veterinary Associates, or NVA, have agreed to divest facilities in three locations to MedVet Associates, LLC, to settle Federal Trade Commission charges that Compassion First’s proposed $5 billion acquisition of NVA would violate federal...
The Federal Trade Commission sued two companies to stop them from continuing to deceive consumers with false claims that their pills are scientifically proven to alleviate joint pain by growing new bone and cartilage.
In February 2020, the FTC filed a complaint in federal district court against ZyCal Bioceuticals, a company that manufactured and sold the ingredient Cyplexinol to trade customers for use in making pain relief products for joint ailments, such as arthritis. Zycal also marketed a line...
